Modern Pediatrics. Ukraine. (2025).1(145): 75-84. doi: 10.15574/SP.2025.1(145).7584
Dubey L. Ya.^1,2, Dubey N. V.¹, Dorosh O. I.^1,2, Kozlova O. I.^1,2, Lytvyn G. O.¹, Kotsai B. R.¹, Lisny А. Y.¹, Kamut N. V.¹, Kuzyk А. S.^1
1Danylo Halytsky Lviv National Medical University, Ukraine
²NCP ENT "Clinical Center of Pediatric Medicine", Lviv, Ukraine

For citation: Dubey LYa, Dubey NV, Dorosh OI, Kozlova OI, Lytvyn GO, Kotsai BR et al. (2025). Fibrinolysis and bleeding of unknown cause. Modern Pediatrics. Ukraine. 1(145): 75-84. doi: 10.15574/SP.2025.1(145).7584.
Article received: Dec 14, 2024. Accepted for publication: Feb 11, 2025.

Patients with Bleeding of Unknown Cause (BUC) have a variety of bleeding symptoms ranging from mild to moderate, but no circulatory disturbances. In clinical practice, hyperfibrinolysis is not sufficiently evaluated as the main cause of bleeding, and there are no commonly known tests for abnormal fibrinolysis.
Aim – to analyse the occurrence of abnormal fibrinolysis and determine the role of specific biomarkers and coagulation tests in its diagnosis, which will improve the understanding and treatment of bleeding in patients with complex coagulation disorders.
Several patients have been reported with distinct fibrinolytic disorders, including α2-antiplasmin deficiency, plasminogen activator inhibitor 1 deficiency, or Quebec platelet disorder. The review aims to summarize data on these established fibrinolytic disorders and discuss the assessment of fibrinolysis in previous cohorts. In addition, we review available global tests with the potential to measure fibrinolysis, such as fibrin clot turbidity assay and rotational thromboelastometry, and their relevance to screening patients with BUC. We concluded that due to the lack of adequate global tests, hyperfibrinolysis may be an underdiagnosed cause of blood coagulation disorders. Diagnosis of hyperfibrinolytic coagulation disorders would improve patient management because effective treatment with antifibrinolytic agents is available.
Conclusions. Detection of hyperfibrinolysis is important in the evaluation of patients with coagulopathy, as it can lead to serious bleeding. The use of antifibrinolytics is an effective treatment. However, complex diagnostic methods, lack of available screening tests and insufficient information about inborn defects in fibrinolytic factors can lead to underestimation of this problem. Future research and newer methods of analysis may improve the diagnosis and treatment of patients with coagulation disorders.
No conflict of interests was declared by the authors.
Keywords: bleeding, blood coagulation disorder, fibrinolysis, plasminogen activators, plasminogen inactivators.

REFERENCES

1. Abstracts Posters of ISTH 2020 Virtual Congress of the International Society on Thrombosis and Haemostasis. (2020). Res Pract Thromb Haemost. 4: 1-1311.

2. Acosta RAH, Garrigos ZE, Marcelin JR, Vijayvargiya P. (2022). COVID-19 Pathogenesis and Clinical Manifestations. Infect Dis Clin North Am. 36(2): 231-249. https://doi.org/10.1016/j.idc.2022.01.003; PMid:35636898 PMCid:PMC8806149

3. Ahmad F, Kannan M, Ansari A.W. (2022). Role of SARS-CoV-2-induced cytokines and growth factors in coagulopathy and thromboembolism. Cytokine Growth Factor Rev. 63: 58-68. https://doi.org/10.1016/j.cytogfr.2021.10.007; PMid:34750061 PMCid:PMC8541834

4. Alexiou A, Batiha GE-S, Al-Kuraishy et al. (2022). Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19. Endocrine Metab. Immune Disord.-Drug Targets. 23: 35-45. https://doi.org/10.2174/1871530322666220801102402; PMid:35927893

5. Cesarman-Maus G, Cantú-Brito C, Barinagarrementeria F et al. (2011). Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis. Stroke. 42(2): 501-3. https://doi.org/10.1161/STROKEAHA.110.592121; PMid:21193750 PMCid:PMC3075847

6. Chandler WL. (2019). Laboratory techniques in fibrinolysis testing. Transfus Med Hemostasis Elsevier: 865‐868. https://doi.org/10.1016/B978-0-12-813726-0.00146-X

7. Chapin JC, Hajjar KA. (2015). Fibrinolysis and the control of blood coagulation. Blood Rev. 29: 17-24. https://doi.org/10.1016/j.blre.2014.09.003; PMid:25294122 PMCid:PMC4314363

8. Connors JM, Levy JH. (2020) Thromboinflammation and the hypercoagulability of COVID-19. J. Thromb. Haemost. 18: 1559-1561. https://doi.org/10.1111/jth.14849; PMid:32302453 PMCid:PMC9770920

9. Conway EM, Mackman N, Warren RQ et al. (2022). Understanding COVID-19-associated coagulopathy. Nat. Rev. Immunol. 22: 639-649. https://doi.org/10.1038/s41577-022-00762-9; PMid:35931818 PMCid:PMC9362465

10. Downes K, Megy K, Duarte D et al. (2019). Diagnostic high‐throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. Blood. 134: 2082‐2091. https://doi.org/10.1182/blood.2018891192; PMid:31064749 PMCid:PMC6993014

11. Edlmann E, Giorgi-Coll S, Whitfield PC et al. (2017). Pathophysiology of chronic subdural haematoma: Inflammation, angiogenesis and implications for pharmacotherapy. J. Neuroinflamm. 14: 1-13. https://doi.org/10.1186/s12974-017-0881-y; PMid:28558815 PMCid:PMC5450087

12. Flood EC, Hajjar KA. (2011). The annexin A2 system and vascular homeostasis. Vascul Pharmacol. 54(3-6): 59-67. https://doi.org/10.1016/j.vph.2011.03.003; PMid:21440088 PMCid:PMC3109204

13. Gebhart J, Hofer S, Kaider A, Rejtö J et al. (2020). The discriminatory power of bleeding assessment tools in adult patients with a mild to moderate bleeding tendency. Eur J Intern Med. 78: 34‐40. https://doi.org/10.1016/j.ejim.2020.04.023; PMid:32317240

14. Hassanpour S, Kim H, Saadati et al. (2020). Thrombolytic Agents: Nanocarriers in Controlled Release. Small. 16: 2001647. https://doi.org/10.1002/smll.202001647; PMid:32790000 PMCid:PMC7702193

15. Ilich A, Bokarev I, Key NS. (2017). Global assays of fibrinolysis. Int J Lab Hematol. 39: 441‐447. https://doi.org/10.1111/ijlh.12688; PMid:28497494

16. Ilich A, Noubouossie DF, Henderson M et al. (2020). Development and application of global assays of hyper‐ and hypofibrinolysis. Res Pract Thromb Haemost. 4: 46‐53. https://doi.org/10.1002/rth2.12275; PMid:31989084 PMCid:PMC6971323

17. Khalafallah A, Jarvis C, Morse M et. al. (2014). Evaluation of the innovance d-dimer assay for the diagnosis of disseminated intravascular coagulopathy in different clinical settings. Clin Appl Thromb Hemost. 20(1): 91-97. https://doi.org/10.1177/1076029612454936; PMid:22859588

18. Longstaff C. (2018). Measuring fibrinolysis: from research to routine diagnostic assays. J. Thromb. Haemost. 16: 652‐662. https://doi.org/10.1111/jth.13957; PMid:29363269 PMCid:PMC5947570

19. Mackman N, Antoniak S, Wolberg AS et al. (2020). Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. Arterioscler. Thromb. Vasc. Biol. 40: 2033-2044. https://doi.org/10.1161/ATVBAHA.120.314514; PMid:32657623 PMCid:PMC7447001

20. Mehic D, Hofer S, Jungbauer C et al. (2020). Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause. Blood Adv. 4: 5157‐5164. https://doi.org/10.1182/bloodadvances.2020002452; PMid:33095871 PMCid:PMC7594405

21. Mezzano D, Quiroga T. (2019). Diagnostic challenges of inherited mild bleeding disorders: a bait for poorly explored clinical and basic research. J. Thromb Haemost. 17: 257‐270. https://doi.org/10.1111/jth.14363; PMid:30562407

22. Rodeghiero F, Pabinger I, Ragni M et al. (2019). Fundamentals for a systematic approach to mild and moderate inherited bleeding disorders. HemaSphere. 3: 1. https://doi.org/10.1097/HS9.0000000000000286; PMid:31942541 PMCid:PMC6919472

23. Srivastava S, Garg I, Bansal A et al. (2020). COVID-19 infection and thrombosis. Clin. Chim. Acta. 510: 344-346. https://doi.org/10.1016/j.cca.2020.07.046; PMid:32712049 PMCid:PMC7377993

24. Steadman E, Fandaros M, Yin W. (2021). SARS-CoV-2 and Plasma Hypercoagulability. Cell. Mol. Bioeng. 14: 513-522. https://doi.org/10.1007/s12195-021-00685-w; PMid:34221178 PMCid:PMC8238024

25. Steinmetzer T, Pilgram O, Wenzel BM et al. (2020). Fibrinolysis inhibitors: potential drugs for the treatment and prevention of bleeding. J Med Chem. 63: 1445‐1472. https://doi.org/10.1021/acs.jmedchem.9b01060; PMid:31658420

26. Van der Hulle T, den Exter PL, Erkens PG et al. (2013). Variable D-dimer thresholds for diagnosis of clinically suspected acute pulmonary embolism. J. Thromb Haemost. 11(11): 1986-1992. https://doi.org/10.1111/jth.12394; PMid:23965032

Van der Hulle T, Tan M, den Exter PL et al.( 2013). Selective D-dimer testing for the diagnosis of acute deep vein thrombosis: a validation study. J. Thromb Haemost. 11(12): 2184-2186. https://doi.org/10.1111/jth.12419; PMid:24119063

27. Veen CSB, Huisman EJ, Cnossen MH et al. (2020). Evaluation of thromboelastometry, thrombin generation and plasma clot lysis time in patients with bleeding of unknown cause: a prospective cohort study. Haemophilia. 26(3): 106‐115. https://doi.org/10.1111/hae.13991; PMid:32337845

29. Westbury SK, Whyte CS, Stephens J et al. (2020). A new pedigree with thrombomodulin‐associated coagulopathy in which delayed fibrinolysis is partially attenuated by co‐inherited TAFI deficiency. J. Thromb Haemost. 18(9): 2209‐2214. https://doi.org/10.1111/jth.14990; PMid:32634856

30. Zheng Z, Nayak L, Wang W et al. (2019). An ATF6‐tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1. Blood. 133: 743‐753. https://doi.org/10.1182/blood-2018-07-864843; PMid:30504459 PMCid:PMC6376283